You just read:

Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer

News provided by

Cell Therapeutics, Inc.

Jan 28, 2014, 01:30 EST